Plain-English translation of NCT07613294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new medication designed to lower Lp(a)—a protein in your blood that increases your risk of heart disease. The study will compare this medication to a placebo (a dummy treatment) to see whether the medication can reduce the buildup of plaque in your heart's arteries over time. Researchers will use special imaging scans to measure any changes in your artery plaque.
High Lp(a) levels significantly increase the risk of heart attack and stroke, but current heart medications don't specifically target Lp(a). This trial exists to test whether this new medication can help reduce Lp(a) and slow or reverse the buildup of dangerous plaque in your coronary arteries.
You likely qualify if…
You likely don't qualify if…
You will participate in this study for about 2.5 years. You'll be randomly assigned to receive either the new medication or a placebo as injections under your skin. Throughout the study, you'll have regular clinic visits for check-ups, blood tests, and imaging scans of your heart arteries (including a special CT scan) to measure whether the treatment is reducing plaque buildup.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States